Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.